Ultrasound elastography in the assessment of post-stroke muscle stiffness: a systematic review

Roots, Jacqueline; Trajano, Gabriel S.; Fontanarosa, Davide

doi:10.1186/s13244-022-01191-x

Cited by 17 publications

(7 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study population had high baseline fatigue levels, which improved post-treatment but remained in the severe category [104]. The change was twice the MCID [90,105] and consistent with meta-analysis data regarding localised PBMT [71].…”

Section: Discussionsupporting

confidence: 83%

Whole-Body Photobiomodulation Therapy for Fibromyalgia: A Feasibility Trial

Fitzmaurice

Heneghan

Rayen

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Effective treatment for fibromyalgia (FM) is lacking and further treatment options are needed. Photobiomodulation therapy (PBMT) represents one potential treatment option. Whilst favourable findings have been reported using localised PBMT, no investigations have established the value of whole-body PBMT for the complete set of symptom domains in FM. Methods A single-arm feasibility study was conducted in accordance to CONSORT (CONsolidated Standards of Reporting Trials) guidelines. A non-probability sampling method was used to access individuals with FM. The primary outcome measure was identified as the Revised Fibromyalgia Impact Questionnaire (FIQR). Forty-nine participants were screened and 21 trial participants entered the trial. Nineteen participants completed the intervention (18 whole-body PBMT sessions over approximately six weeks). Descriptive statistics and qualitative analysis was undertaken to represent feasibility outcomes. Acceptability of the trial device and processes were established. Outcome measures towards efficacy data were guided by core and peripheral OMERACT (outcomes measures in rheumatological clinical trials) domains, utilising a combination of participant-reported and performance-based outcome measures. Data for the embedded qualitative component of the trial were captured by participant-reported experience measures and audio-recorded semi-structured interviews. Results Positive changes were observed for FM-specific quality of life, pain, tenderness, stiffness, fatigue, sleep disturbance, anxiety, depression and cognitive impairment. Patient global assessment revealed improvements at 6 weeks, with continued effect at 24 weeks. FM-specific quality of life at 24 weeks remained improved compared with baseline scores. Conclusions Findings provide evidence to support a full-scale trial and shows promise regarding potential efficacy of this novel non-invasive treatment in an FM population. Trial Registration ClinicalTrials.gov trial; NCT05069363, 06/10/2021

show abstract

Section: Discussionsupporting

confidence: 83%

Whole-Body Photobiomodulation Therapy for Fibromyalgia: A Feasibility Trial

Fitzmaurice

Heneghan

Rayen

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…This study population had high baseline fatigue levels, which improved post-treatment but remained in the severe category [77]. The change was twice the MCID [97,106] and consistent with meta-analysis data regarding localised PBMT [134]. Fatigue is multidimensional and its aetiological mechanism is not fully understood [13].…”

Section: Discussionsupporting

confidence: 78%

Whole-Body Photobiomodulation Therapy for Fibromyalgia: A Feasibility Trial

Fitzmaurice

Heneghan

Rayen

et al. 2023

Preprint

View full text Add to dashboard Cite

Effective treatment for fibromyalgia (FM) is lacking and further treatment options are needed. Photobiomodulation therapy (PBMT) represents one potential treatment option. Whilst favourable findings have been reported using localised PBMT, no investigations have established the value of whole-body PBMT for the complete set of symptom domains in FM. A single-arm feasibility study was conducted in accordance to CONSORT guidelines. A non-probability sampling method was used to access individuals with FM. The primary outcome measure was identified as the Revised Fibromyalgia Impact Questionnaire (FIQR). Forty-nine participants were screened and 21 trial participants entered the trial. Nineteen participants completed the intervention (18 whole-body PBMT sessions over approximately six weeks). Descriptive statistics and qualitative analysis was undertaken to represent feasibility outcomes. Acceptability of the trial device and processes were established. Outcome measures towards efficacy data were guided by core and peripheral OMERACT domains, utilising a combination of participant-reported and performance-based outcome measures. Positive changes were observed for FM-specific quality of life, pain, tenderness, stiffness, fatigue, sleep disturbance, anxiety, depression and cognitive impairment. Patient global assessment revealed improvements at 6 weeks, with continued effect at 24 weeks. FM-specific quality of life at 24 weeks remained improved compared with baseline scores. Data for the embedded qualitative component of the trial were captured by participant-reported experience measures and audio-recorded semi-structured interviews. Findings provide evidence to support a full-scale trial and shows promise regarding potential efficacy of this novel non-invasive treatment in an FM population.

show abstract

“…Furthermore, studies did not reliably show that quantitative stiffness correlates to symptom burden in the FM population [ 132 , 133 ]. Recent studies have shown promise in this technique in assessing post-stroke stiffness [ 134 ], but further research to validate this technique in the FM population is warranted.…”

Section: Discussionmentioning

confidence: 99%

Whole-Body Photobiomodulation Therapy for Fibromyalgia: A Feasibility Trial

Fitzmaurice,

Heneghan,

Rayen

et al. 2023

Behavioral Sciences

View full text Add to dashboard Cite

Effective treatment for fibromyalgia (FM) is lacking and further treatment options are needed. Photobiomodulation therapy (PBMT) represents one potential treatment option. Whilst favourable findings have been reported using localised PBMT, no investigations have established the value of whole-body PBMT for the complete set of symptom domains in FM. A single-arm feasibility study was conducted in accordance with CONSORT (Consolidated Standards of Reporting Trials) guidelines. A non-probability sampling method was used to access individuals with FM. The primary outcome measure was identified as the Revised Fibromyalgia Impact Questionnaire (FIQR). Forty-nine participants were screened and twenty-one trial participants entered the trial. Nineteen participants completed the intervention (18 whole-body PBMT sessions over approximately six weeks). Descriptive statistics and qualitative analysis was undertaken to represent feasibility outcomes. Acceptability of the trial device and processes were established. Outcome measures towards efficacy data were guided by core and peripheral OMERACT (outcomes measures in rheumatological clinical trials) domains, utilising a combination of participant-reported and performance-based outcome measures. Data for the embedded qualitative component of the trial were captured by participant-reported experience measures and audio-recorded semi-structured interviews. Positive changes were observed for FM-specific quality of life, pain, tenderness, stiffness, fatigue, sleep disturbance, anxiety, depression and cognitive impairment. Patient global assessment revealed improvements at 6 weeks, with continued effect at 24 weeks. FM-specific quality of life at 24 weeks remained improved compared with baseline scores. The findings provided evidence to support a full-scale trial and showed promise regarding potential efficacy of this novel non-invasive treatment in an FM population.

show abstract

Ultrasound elastography in the assessment of post-stroke muscle stiffness: a systematic review

Cited by 17 publications

References 50 publications

Whole-Body Photobiomodulation Therapy for Fibromyalgia: A Feasibility Trial

Whole-Body Photobiomodulation Therapy for Fibromyalgia: A Feasibility Trial

Whole-Body Photobiomodulation Therapy for Fibromyalgia: A Feasibility Trial

Whole-Body Photobiomodulation Therapy for Fibromyalgia: A Feasibility Trial

Contact Info

Product

Resources

About